Recombinant Human FGF2, Pro143-Ser288, was produced in E. coli using non-animal reagents in an animal-free facility under cGMP guidelines.
Lyophilized from a 0.2 μm filtered solution in Tris-HCl and NaCl.
Measured in a cell proliferation assay using NR6R‑3T3 mouse fibroblast cells. Raines, E.W. et al. (1985) Methods Enzymol. 109:749. The ED50 for this effect is 0.1-0.6 ng/mL.
The specific activity of Recombinant Human FGF basic GMP is approximately 800 IU/μg, which is calibrated against human FGF basic WHO International Standard (NIBSC code: 90/712).
Predicted Molecular Mass: 16.5 kDa
SDS-PAGE: 17 kDa, reducing conditions
N-terminal Sequence Analysis:
<0.10 EU per 1 μg of the protein by the LAL method.
>97%, by SDS-PAGE with silver staining.
Avoid repeated freeze-thaw cycles.
12 months, -20 to -70 centigrade as supplied.
1 month, 2 to 8 centigrade under sterile conditions after reconstitution.
3 months, -20 to -70 centigrade under sterile conditions after reconstitution.
Reconstitute at 100 μg/mL in PBS.
Our GMP proteins are produced according to relevant sections of the following documents: WHO TRS, No. 822, 1992 Annex 1, Good Manufacturing Practices for Biological Products; USP Chapter 1043, Ancillary Materials for Cell, Gene and Tissue-Engineered Products and USP Chapter 92, Growth Factors and Cytokines Used in Cell Therapy Manufacturing.
The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.